Icatibant Acetate 相關新聞
Icatibant Acetate 目前有 0 則相關新聞報導,預測適應症 20 個。
本頁整合 Icatibant Acetate 的 AI 預測適應症與最新健康新聞,橘色標示的適應症表示近期有相關新聞報導。
藥物資訊
- 原適應症:Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor...
- 證據等級:L5
- 預測適應症(20 個):
- C1 inhibitor deficiency(100.0%)
- hereditary angioedema with C1Inh deficiency(100.0%)
- serpinopathy with toxic serpin polymerization(100.0%)
- hereditary angioedema(99.4%)
- pseudo-von Willebrand disease(99.2%)
- primary release disorder of platelets(99.1%)
- immune-mediated necrotizing myopathy(99.1%)
- antisynthetase syndrome(99.0%)
- Glanzmann thrombasthenia(99.0%)
- focal myositis(99.0%)
- Scott syndrome(98.8%)
- inflammatory myopathy with abundant macrophages(98.8%)
- idiopathic eosinophilic myositis(98.8%)
- Peyronie disease(98.6%)
- pancreatitis(98.0%)
- pernicious anemia(97.9%)
- thrombotic thrombocytopenic purpura(97.9%)
- inherited thrombophilia(97.4%)
- selective IgG immunodeficiency(97.3%)
- bleeding diathesis due to a collagen receptor defect(97.3%)
相關新聞(0 則)
目前沒有相關新聞報導。當有新聞提到此藥物時,系統會自動收集並顯示在這裡。
免責聲明:本頁新聞由系統自動收集,僅供研究參考,不構成醫療建議。